Literature DB >> 21115053

Highly effective generic adjuvant systems for orphan or poverty-related vaccines.

Mangala Rao1, Kristina K Peachman, Qin Li, Gary R Matyas, Sathish B Shivachandra, Richard Borschel, Venee I Morthole, Carmen Fernandez-Prada, Carl R Alving, Venigalla B Rao.   

Abstract

Safe and effective adjuvants are needed for many vaccines with limited commercial appeal, such as vaccines to infrequent (orphan) diseases or to neglected and poverty-related diseases. Here we found that three nonproprietary liposome formulations containing monophosphoryl lipid A each induced 3-fold to 5-fold increased titers of binding and neutralizing antibodies to anthrax protective antigen compared to aluminum hydroxide-adsorbed antigen in monkeys. All vaccinated monkeys were protected against lethal challenge with aerosolized Ames strain spores. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21115053      PMCID： PMC4190060          DOI： 10.1016/j.vaccine.2010.11.049

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  27 in total

Review 1.  The perfect mix: recent progress in adjuvant research.

Authors:  Bruno Guy
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

Review 2.  New adjuvants: EU regulatory developments.

Authors:  Dorothea Sesardic; Sjoerd Rijpkema; Brijesh Prakash Patel
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

Review 3.  New horizons in adjuvants for vaccine development.

Authors:  Steven G Reed; Sylvie Bertholet; Rhea N Coler; Martin Friede
Journal:  Trends Immunol       Date:  2008-12-06       Impact factor: 16.687

Review 4.  Vaccine adjuvants: scientific challenges and strategic initiatives.

Authors:  Ali M Harandi; Gwyn Davies; Ole F Olesen
Journal:  Expert Rev Vaccines       Date:  2009-03       Impact factor: 5.217

5.  Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery.

Authors:  J M Muderhwa; G R Matyas; L E Spitler; C R Alving
Journal:  J Pharm Sci       Date:  1999-12       Impact factor: 3.534

Review 6.  Advances in the development of next-generation anthrax vaccines.

Authors:  Arthur M Friedlander; Stephen F Little
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

7.  Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.

Authors:  B E Ivins; M L Pitt; P F Fellows; J W Farchaus; G E Benner; D M Waag; S F Little; G W Anderson; P H Gibbs; A M Friedlander
Journal:  Vaccine       Date:  1998-07       Impact factor: 3.641

Review 8.  Vaccines: countering anthrax: vaccines and immunoglobulins.

Authors:  John D Grabenstein
Journal:  Clin Infect Dis       Date:  2008-01-01       Impact factor: 9.079

Review 9.  GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives.

Authors:  Nathalie Garçon; Patrick Chomez; Marcelle Van Mechelen
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

Review 10.  Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.

Authors:  Nancy J Sullivan; Julie E Martin; Barney S Graham; Gary J Nabel
Journal:  Nat Rev Microbiol       Date:  2009-05       Impact factor: 60.633
View more
  16 in total

Review 1.  Adjuvants for human vaccines.

Authors:  Carl R Alving; Kristina K Peachman; Mangala Rao; Steven G Reed
Journal:  Curr Opin Immunol       Date:  2012-04-19       Impact factor: 7.486

Review 2.  Structure, assembly, and DNA packaging of the bacteriophage T4 head.

Authors:  Lindsay W Black; Venigalla B Rao
Journal:  Adv Virus Res       Date:  2012       Impact factor: 9.937

3.  Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.

Authors:  Gary R Matyas; Alexander V Mayorov; Kenner C Rice; Arthur E Jacobson; Kejun Cheng; Malliga R Iyer; Fuying Li; Zoltan Beck; Kim D Janda; Carl R Alving
Journal:  Vaccine       Date:  2013-04-23       Impact factor: 3.641

Review 4.  Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.

Authors:  Pan Tao; Jingen Zhu; Marthandan Mahalingam; Himanshu Batra; Venigalla B Rao
Journal:  Adv Drug Deliv Rev       Date:  2018-07-06       Impact factor: 15.470

5.  Bacteriophage T4 as a Nanoparticle Platform to Display and Deliver Pathogen Antigens: Construction of an Effective Anthrax Vaccine.

Authors:  Pan Tao; Qin Li; Sathish B Shivachandra; Venigalla B Rao
Journal:  Methods Mol Biol       Date:  2017

6.  A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering.

Authors:  Jingen Zhu; Neeti Ananthaswamy; Swati Jain; Himanshu Batra; Wei-Chun Tang; Douglass A Lewry; Michael L Richards; Sunil A David; Paul B Kilgore; Jian Sha; Aleksandra Drelich; Chien-Te K Tseng; Ashok K Chopra; Venigalla B Rao
Journal:  Sci Adv       Date:  2021-09-08       Impact factor: 14.957

Review 7.  Army Liposome Formulation (ALF) family of vaccine adjuvants.

Authors:  Carl R Alving; Kristina K Peachman; Gary R Matyas; Mangala Rao; Zoltan Beck
Journal:  Expert Rev Vaccines       Date:  2020-03-31       Impact factor: 5.217

8.  A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.

Authors:  Melissa A Kachura; Colin Hickle; Sariah A Kell; Atul Sathe; Carlo Calacsan; Radwan Kiwan; Brian Hall; Robert Milley; Gary Ott; Robert L Coffman; Holger Kanzler; John D Campbell
Journal:  J Immunol       Date:  2015-11-25       Impact factor: 5.422

9.  Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.

Authors:  Kristina K Peachman; Qin Li; Gary R Matyas; Sathish B Shivachandra; Julie Lovchik; Rick C Lyons; Carl R Alving; Venigalla B Rao; Mangala Rao
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

Review 10.  Prophylactic vaccine delivery systems against epidemic infectious diseases.

Authors:  Chao Pan; Hua Yue; Li Zhu; Guang-Hui Ma; Heng-Liang Wang
Journal:  Adv Drug Deliv Rev       Date:  2021-07-17       Impact factor: 17.873
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.